Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
49 participants
INTERVENTIONAL
2017-01-01
2018-09-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active tDCS + In Vivo Exposure
Participants assigned to this condition will receive excitatory transcranial direct current stimulation (tDCS) of the left medial prefrontal cortex (lmPFC) and inhibitory tDCS of right dorsolateral prefrontal cortex (rdlPFC). tDCS will be administered for 20 minutes at 1.7 mA, followed by 30 minutes of in vivo exposure therapy.
Transcranial Direct Current Stimulation (tDCS)
Participants will receive 20 minutes of either active or sham tDCS prior to in vivo exposure to feared targets.
In vivo exposure therapy
Participants will receive 30 minutes of in vivo exposure to feared targets following either active or sham tDCS
sham tDCS + In Vivo Exposure
Participants assigned to this condition will receive sham transcranial direct current stimulation (tDCS), which will consist of 30 seconds of stimulation at the beginning and end of tDCS administration. Electrode positioning will be counterbalanced across participants (i.e., either mPFC+ or mPFC-, with same electrode positioning as the active comparators). Sham tDCS will be administered for 20 minutes, followed by 30 minutes of in vivo exposure therapy.
In vivo exposure therapy
Participants will receive 30 minutes of in vivo exposure to feared targets following either active or sham tDCS
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transcranial Direct Current Stimulation (tDCS)
Participants will receive 20 minutes of either active or sham tDCS prior to in vivo exposure to feared targets.
In vivo exposure therapy
Participants will receive 30 minutes of in vivo exposure to feared targets following either active or sham tDCS
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Fluent in English.
3. A score on at least 1 fear domain-specific prescreen measure \> 2 SDs above the subject pool prescreen mean. These measures include (a) FSQ, and (b) OCI-R.
4. Peak fear ≥ 50 on BATs 1 and 2.
Exclusion Criteria
2. Unstable dose of psychotropic medications within 6 weeks prior to baseline assessment (based on the DMQ; see measures).
3. Medical condition that would contraindicate participation in treatment or assessment activities (e.g., cardiovascular problems; based on the DMQ; see measures).
4. Pregnancy (based on the DMQ; see measures).
5. Current major depressive disorder (based on MINI; see measures).
6. Current, or history of bipolar disorder (based on MINI; see measures).
7. Current, or history of psychotic symptoms (based on MINI; see measures).
8. Serious suicidal risk, as determined by self-report (C-SSRS, BDI-II) and clinical interview (MINI; see measures).
9. Active neurological conditions, including seizures, stroke, unexplained loss of consciousness or concussion (based on DMQ and tDCS Safety Screening Form; see measures)
10. Contraindications for tDCS: Metal in the head or implanted brain medical devices.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Texas at Austin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Michael J. Telch
Professor of Psychology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adam R. Cobb, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
The University of Texas at Austin
Michael J. Telch, PhD
Role: STUDY_DIRECTOR
The University of Texas at Austin
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Laboratory for the Study of Anxiety Disorders
Austin, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Website for the Laboratory for the Study of Anxiety Disorders
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-02-0024
Identifier Type: -
Identifier Source: org_study_id